Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Ugeskr Laeger ; 184(34)2022 08 22.
Artigo em Dinamarquês | MEDLINE | ID: mdl-36065862

RESUMO

Autism spectrum disorders (ASD) have a complex genetic component comprising both frequent polygenic and rare monogenic factors. Research is conducted in methods used to calculate polygenic risk scores, which are not applicable in clinical practice. Advances in genomic technology have identified several monogenic causes, and genetic testing may be offered to persons with ASD where a monogenic etiology is suspected. Herein, we provide an overview of the current knowledge and present the first national recommendation regarding genetic testing in ASD.


Assuntos
Transtorno do Espectro Autista , Transtorno do Espectro Autista/diagnóstico , Transtorno do Espectro Autista/genética , Predisposição Genética para Doença , Testes Genéticos , Genômica , Humanos
2.
Infect Dis (Lond) ; 47(8): 517-22, 2015 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-25831259

RESUMO

BACKGROUND: Vaccination guidelines from the Danish Health and Medicines Authority recommend vaccination of all men who have sex with men (MSM) against hepatitis B virus (HBV). The only existing data on HBV infection in Danish MSM stem from 1984: 58% of MSM attending venereal clinics in Copenhagen had a prior and 4% had a chronic HBV infection. The aim of this study was to provide up-to-date data on the prevalence of HBV infection and vaccination coverage among Danish MSM. METHODS: At the venereal clinic at Aarhus University Hospital, 1525 consecutive patients received a questionnaire covering risk group and vaccination status; moreover, HBV serology was performed. Prevalence proportions of serological signs of vaccination, infection, etc. were stratified according to self-reported risk group and vaccination status. RESULTS: In total, 141 patients were MSM. Among these, 14% (CI = 9-21%) were vaccinated, 7% (CI = 3-13%) had a prior infection and 1.4% (CI = 0.2-5%) were HBsAg positive. In patients recalling three doses of vaccination, 18% (CI = 11-26%) were anti-HBs negative and 0.8% (CI = 0.02-5%) were HBsAg positive. Similar data for other risk groups and the total clientele are presented. CONCLUSIONS: This study presents the first Scandinavian data on the prevalence of HBV infection and vaccination among MSM since the introduction of the vaccine. Danish health authorities should evaluate whether a carrier frequency of 1.4% and a vaccination coverage of 14% in MSM is acceptable or warrants intensified focus on vaccination. Prospective vaccination campaigns should consider prevaccination testing, since 18% of patients recalling three doses of vaccination were anti-HBs negative.


Assuntos
Assistência Ambulatorial/estatística & dados numéricos , Vacinas contra Hepatite B , Hepatite B/epidemiologia , Homossexualidade Masculina , Vacinação/estatística & dados numéricos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Dinamarca/epidemiologia , Hepatite B/prevenção & controle , Anticorpos Anti-Hepatite B/sangue , Anticorpos Anti-Hepatite B/imunologia , Proteínas de Homeodomínio , Humanos , Masculino , Pessoa de Meia-Idade , Prevalência , Estudos Prospectivos , Fatores de Risco , Testes Sorológicos , Infecções Sexualmente Transmissíveis/prevenção & controle , Inquéritos e Questionários , Adulto Jovem
3.
J Infect ; 64(4): 399-408, 2012 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-22227464

RESUMO

OBJECTIVES: To assess journey length and other predictors of travel-related acute hepatitis A (HAV) and B (HBV) virus infection among native Danes and determine the sensitivity and specificity of current pre-travel vaccination guidelines. METHODS: A nationwide case-control study was perfomed involving 60 Danes with HAV and 14 with HBV who acquired hepatitis in non-western countries from 2000 to 2010. Non-immune travellers from a nationwide survey (1188 HAV and 1709 HBV) served as controls. RESULTS: The odds ratios (ORs) for HAV and HBV increased with increasing journey length (p<0.0001). However, 90% of HAV and 62% of HBV cases travelled for less than 4 weeks, and the daily infection rate did not increase with journey length; rather, for HAV it decreased. Increasing age (p<0.0001) and journeys to Africa (OR 6.1 (3.2-11)) raised the risk of acute HAV. Travelling alone or with friends as compared to travelling with a partner/family (OR: 15 (3.2-134)) strongly predicted HBV risk. Danish vaccination guidelines had HAV/HBV sensitivities of 86%/31%, and specificities of 27%/95%, respectively. Incidence rates were 12.8 (HAV) and 10.2 (HBV) per 100,000 non-immune travel months, and acute disease severity affected HAV and HBV cases equally. CONCLUSIONS: These results may support revision of current pre-travel vaccination guidelines.


Assuntos
Vacinas contra Hepatite A/uso terapêutico , Hepatite A/epidemiologia , Vacinas contra Hepatite B/uso terapêutico , Hepatite B/epidemiologia , Imunização/normas , Viagem , Adolescente , Adulto , Idoso , Estudos de Casos e Controles , Dinamarca/epidemiologia , Feminino , Hepatite A/prevenção & controle , Hepatite A/virologia , Hepatite B/prevenção & controle , Hepatite B/virologia , Humanos , Masculino , Pessoa de Meia-Idade , Guias de Prática Clínica como Assunto , Valor Preditivo dos Testes , Fatores de Risco , Sensibilidade e Especificidade , Fatores de Tempo , Adulto Jovem
4.
J Infect ; 59(5): 353-9, 2009 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-19733194

RESUMO

OBJECTIVES: The authors examine the rationale and efficacy of pre-travel hepatitis B immunization strategies based on itinerary and presumed on-travel risk behaviour. METHODS: A large survey among 26,640 Danes survey provided data on journey lengths and destinations, immunization coverage, risk behaviour and knowledge. RESULTS: The estimated cumulative lifetime stay in endemic areas outside Europe is 4.3 months. The majority of risk situations are involuntary and unforeseeable. The majority of risk situations occur on short-term journeys. 5% nonimmune and 5% short-term travellers experienced at least one risk situation such as injections/operations/tattoos on their journey. The level of knowledge of hepatitis A and B is low. CONCLUSIONS: The rationale and efficacy of current immunization strategies are challenged. Based on the results presented here and the availability of vaccines with long-lasting coverage, the authors find that recommendations of immunization should be based on lifetime risk instead of single journey itineraries. The authors find that a recommendation and/or cost-benefit discussion would be relevant in the pre-travel counselling of most - especially younger - travellers to endemic areas.


Assuntos
Vacinas contra Hepatite B , Hepatite B/prevenção & controle , Assunção de Riscos , Viagem/psicologia , Vacinação/métodos , Adolescente , Adulto , Idoso , Dinamarca , Revelação/estatística & dados numéricos , Feminino , Hepatite B/psicologia , Atividades Humanas/estatística & dados numéricos , Humanos , Masculino , Pessoa de Meia-Idade , Racionalização , Fatores de Risco , Viagem/estatística & dados numéricos , Sexo sem Proteção/estatística & dados numéricos , Vacinação/psicologia , Adulto Jovem
5.
J Infect ; 58(1): 47-52, 2009 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-19059649

RESUMO

The authors present a descriptive study on hepatitis A among Danish travellers in the period 1980-2007 based on data from a large survey among 26,640 Danes regarding travel habits, as well as national surveillance and population data. There are five messages to be read from the results: (1) The incidence of hepatitis A is declining at most destinations worldwide. (2) Reported incidence rates tend to overestimate the risk for the average tourist because they include immigrants visiting friends and family in the country of origin. (3) The immunization strategy in Denmark (leaving it up to the individual traveller to seek advice and pay for the immunization) seems to work well for most Danish travellers as 75% travelled immune. (4) Danes travel very frequently to hepatitis A endemic areas and will spend on average 6 months in endemic areas from the age of 18 till 79. (5) 80% of all incident cases 2002-2006 were immigrants or children of immigrants. The immunization strategy is not effective in this group. In conclusion, the risk of acquiring hepatitis A abroad is low for the average ethnic Danish tourist, while it is high in immigrants and their children. Thus, special focus on this group of travellers is warranted.


Assuntos
Hepatite A/epidemiologia , Viagem , Adolescente , Adulto , Idoso , Criança , Dinamarca/epidemiologia , Emigrantes e Imigrantes , Feminino , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Adulto Jovem
6.
Ugeskr Laeger ; 170(19): 1663, 2008 May 05.
Artigo em Dinamarquês | MEDLINE | ID: mdl-18489882

RESUMO

UNLABELLED: A young man with daily nipple discharge was told to wait and see. After 18 months, at 32, he developed a subareolar lump which proved to be invasive ductal carcinoma. There were no epidemiological or genetic risk factors, no mutations in BRCA 1 + 2. Male breast cancer (MBC) patients have a lower survival rate than females due to a delay in diagnosis. Greater focus on MBC is necessary in order to change this. TREATMENT: We chose to follow the guidelines for young women. Some studies imply that early MBC is more benign but there are no randomised trials on treatment.


Assuntos
Neoplasias da Mama Masculina , Carcinoma Ductal de Mama , Adulto , Neoplasias da Mama Masculina/diagnóstico , Neoplasias da Mama Masculina/tratamento farmacológico , Neoplasias da Mama Masculina/cirurgia , Carcinoma Ductal de Mama/diagnóstico , Carcinoma Ductal de Mama/tratamento farmacológico , Carcinoma Ductal de Mama/cirurgia , Humanos , Masculino , Mamilos/metabolismo , Prognóstico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA